Page 74 - SPONDYLOARTHRITIS IN COLOMBIA -

Table 1. Demographic, disease characteristics and comorbidities of the Latin America COMOSPA study
countries and the global ASAS-
Characteristic
Number of patients 3984
ASAS-
Latin America 390
63.8
44.6 (14.7) 42.6
16.7
7.0 (8.1)
84.2 73.9 62.5 23.8 15.8 23.0
3.3
1.9 (1.1) 3.4 (2.8) 71.8 47.6 43.5 34.1
Argentina
236
61.9
45.4 (14.5) 34.7
22.0
6.7 (8.3)
78.3 77.0 57.9 25.5 14.9 33.2
3.4
1.8 (1.1) 3.1 (2.8) 71.9 48.7 25.4 35.6
Colombia
85
60.0
44.1 (13.9) 50.6
10.6
5.2 (5.6)
92.9 70.6 77.6 24.7 11.8
4.7
3.5
2.0 (1.0) 4.3 (2.2) 68.2 42.3 70.2 36.4
México
69
75.4
42.6 (16.3) 59.4
5.8
9.3 (8.7)
94.0 67.2 59.7 16.4 23.9 10.4
3.0
1.8 (1.4) 3.7 (3.0) 76.1 50.7
87 26.1
COMOSPA
Male gender
Age (years)
Education level (university) Smoking status (current) Disease duration (years) Disease symptoms
➢ Axial involvement ➢ Arthritis
➢ Enthesitis
➢ Dactylitis
➢ Uveitis ➢ Psoriasis ➢ IBD
ASDAS-CRP
BASFI
NSAIDS use (last 3 months) Methotrexate (ever) Sulfasalazine (ever) Biological (TNFi) (ever)
65.0
44 (14) 42.4 23.0
8.2 (9.4)
88.7 56.4 38.0 15.6 20.3 22.5
5.2
2.0 (1.1) 3.0 (2.7) 67.8 32.7 43.9 43.9
All values are N (%) or mean (SD) for categorical and continuous variables, respectively IBD, inflammatory bowel disease
Prevalence of comorbidities and risk factors
The prevalence of AHT limited to SpA patients in Colombia and Mexico was higher (21.4%, 95%CI 15.4 to 28.9) as compared to the general-population (12.5%, 95%CI 11.4 to 13.7) in these two countries. The prevalence of AHT was higher in men than in women, especially in the stratum of 55- 64 years (57% vs 11%, respectively) and also in patients ≥65 years (70% vs 25%, respectively), in whom cardiovascular risk is expected to be more similar in both genders. Additionally, in young patients (25-44 years) the prevalence of AHT was consistently increased in both genders compared to the general-population. All of these findings were consistent with the prevalence data of the global ASAS-COMOSPA-study. The total AHT risk of patients with SpA in Colombia and Mexico between 24 and 64 years was increased (SRR: 1.5) compared to the general-population. This risk
72